Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-288164
Filing Date
2025-11-19
Accepted
2025-11-19 16:30:32
Documents
18
Period of Report
2025-12-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A rkda-20251119.htm   iXBRL DEF 14A 1224529
2 GRAPHIC img71583808_0.jpg GRAPHIC 29171
3 GRAPHIC img71583808_1.jpg GRAPHIC 75167
4 GRAPHIC img71583808_2.jpg GRAPHIC 78944
5 GRAPHIC img71583808_3.jpg GRAPHIC 73308
6 GRAPHIC img71583808_4.jpg GRAPHIC 102203
  Complete submission text file 0001193125-25-288164.txt   3023367

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rkda-20251119.xsd EX-101.SCH 17086
20 EXTRACTED XBRL INSTANCE DOCUMENT rkda-20251119_htm.xml XML 294626
Mailing Address 5956 SHERRY LANE SUITE 2000 DALLAS TX
Business Address 5956 SHERRY LANE SUITE 2000 DALLAS TX 214-974-8921
Arcadia Biosciences, Inc. (Filer) CIK: 0001469443 (see all company filings)

EIN.: 810571538 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37383 | Film No.: 251499728
SIC: 1311 Crude Petroleum & Natural Gas
(CF Office: 01 Energy & Transportation)